Abstract
Kynurenic acid (KYNA) is an astrocyte-derived metabolite of the kynurenine pathway of tryptophan degradation and antagonist of alpha7 nicotinic acetylcholine and N-methyl-D-aspartate receptors, and its levels are elevated in the prefrontal cortex of individuals with schizophrenia. Because endogenous KYNA modulates extracellular glutamate, dopamine and GABA levels in the brain, these increases may be pathophysiologically significant. The presentation will review the latest insights into KYNA neurobiology and provide an update on translationally relevant efforts to manipulate KYNA levels in the mammalian brain.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
